Retreatment With CTL019/CTL119

Study Overview
=================
Brief Summary
-----------------
This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

Detailed Description
-----------------
This is a single arm open label trial that will assess the safety and efficacy of retreatment with CTL019/CTL119 chimeric antigen receptor (CAR) modified T cells in patients who have late relapse of diffuse large B-cell or follicular lymphoma after achieving complete remission from prior CTL019/CTL119 treatment. Patients eligible for this protocol will have been treated initially with CTL019/CTL119 under UPCC13413/NCT02030834, have experienced a durable complete response (defined as ≥ 6 months duration), and have a residual manufactured CTL019/CTL119 product available. This protocol will serve subjects with no available potentially curative treatment options (such as autologous or allogeneic stem cell transplantation) who have a limited prognosis (months to < 2 year expected survival) with available therapies.

Official Title
-----------------
Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell Lymphomas

Conditions
-----------------
Lymphoma, B-Cell

Intervention / Treatment
-----------------
* Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diffuse Large B-Cell Lymphoma or Follicular lymphoma, previously identified as CD19+ Previously treated on UPCC13413/ NCT02030834 with CTL019/CTL119, with historical manufactured product available at Penn for reinfusion Previous complete response to CAR T-cells with a duration ≥ 6 months (defined as 168 days) No available curative treatment options (such as autologous or allogeneic HSCT) with limited prognosis (several months to < 2 year survival) with currently available therapies. Age ≥18 years Creatinine < 1.6 mg/dL ALT/AST < 3x upper limit of normal Bilirubin < 2.0 mg/dL, unless subject has Gilbert's Syndrome (≤3.0 mg/dL) Measurable or assessable disease according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., J. Clin. Onc., 2007)88. Patients in complete remission with no evidence of disease are not eligible. Performance status (ECOG) 0 or 1. Left Ventricle Ejection Fraction (LVEF) > 40% confirmed by ECHO/MUGA Agree to contraceptive requirements outlined in Section 4.3. Provide written informed consent. Exclusion Criteria: Uncontrolled active infection. Active hepatitis B or hepatitis C infection. Any uncontrolled active medical disorder that would preclude participation as outlined. Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 1). HIV infection. Patients with active CNS involvement by malignancy. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Retreatment with CTL019/CTL119<br>All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures. | Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)<br>* Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Safety of retreatment with CTL019/CTL119 as measured by treatment-related events | At time of consent through 1 year after the subject received CTL019/CTL119 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate using Cheson 2007 criteria | Efficacy of retreatment with CTL019/CTL119 as measured by ORR by Cheson 2007 definitions at 3 months | Month 3 post-infusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CTL019, CTL119, CAR T-cell, CART